Skip to content
Synthetic Lethality Explained: Targeting Cancer’s DNA Repair Weaknesses episode artwork

Sep 15, 2026 25 min

Synthetic Lethality Explained: Targeting Cancer’s DNA Repair Weaknesses

from Rx for Biotech Hosted by Podcast Host Christopher Leidli

Can precision oncology help identify cancer’s genetic weaknesses and turn them into therapeutic opportunities? In this episode of "Rx for Biotech", host Chris Leidli speaks with Oren Gilad, CEO of Aprea Therapeutics, about the rapidly evolving field of synthetic lethality, DNA damage response, and targeted cancer therapies designed to exploit vulnerabilities in cancer cells. Oren shares how his scientific journey began at the University of Pennsylvania, where early experiments studying ATR helped shape the foundation for Aprea’s current cancer drug development strategy. That work led to a central insight behind synthetic lethality: cancer cells with specific genetic mutations may become highly dependent on certain DNA repair and checkpoint pathways for survival. Aprea is developing a pipeline of precision oncology therapies focused on what Oren describes as multiple targets in one critical pathway, including WEE1, ATR, p53 reactivation, and DYRK1 inhibition. A major focus of the conversation is APR-1051, Aprea’s investigational oral WEE1 inhibitor, which is being studied in patients with cancers carrying specific genetic alterations. Oren explains how WEE1 functions as a checkpoint in cell division, why cancer cells can become especially dependent on this pathway, and how inhibiting WEE1 may selectively target tumor cells while aiming to preserve a wider therapeutic window. This episode is especially relevant for anyone interested in precision medicine, targeted cancer therapy, DNA repair, synthetic lethality, oncology clinical trials, cancer biomarkers, and the future of drug development. Subscribe to Rx for Biotech podcast for conversations with biotech CEOs, scientists, physicians, and industry leaders developing the next generation of personalized medicines. This podcast is for educational purposes only and should not be interpreted as medical advice. Investigational therapies discussed in this episode have not necessarily been established as safe or effective by regulatory authorities.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Synthetic Lethality Explained: Targeting Cancer’s DNA Repair Weaknesses

0:00 25:31

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Rx for Biotech?

This episode is 25 minutes long.

When was this Rx for Biotech episode published?

This episode was published on September 15, 2026.

Can I download this Rx for Biotech episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.